SEARCH

SEARCH BY CITATION

References

  • 1
    Bos, J.L., Verlan de Vries, M., Van Der Eb, A.J., Janssen, J.W.G., Delwel, R., Lowenberg, B., Colly, L.P. (1987) Mutations in N-ras predominate in acute myeloid leukemia. Blood, 69, 1237 1241.
  • 2
    Bradley, T.R., Hodgson, G.S., Rosendaal, M. (1978) The effect of oxygen tension on haemopoietic and fibroblast cell proliferation in vitro. Journal of Cellular Physiology, 97, 517 522.
  • 3
    Buchwald, H. (1992) Cholesterol inhibition, cancer and chemotherapy. Lancet, 339, 1154 1156.
  • 4
    Collins, S. & Groudine, M. (1982) Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line . Nature, 298, 679 681.
  • 5
    Dricu, A., Wang, M., Hjertman, M., Malec, M., Blegen, H., Wejde, J., Carlberg, M., Larsson, O. (1997) Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology, 7, 625 633.
  • 6
    Gibbs, J.B., Oliff, A., Kohl, N.E. (1994) Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell, 77, 175 178.
  • 7
    Girgert, R., Marini, P., Janessa, A., Bruchelt, G., Treuner, J., Schweizer, P. (1994) Inhibition of the membrane localisation of p21 ras proteins by lovastatin in tumor cells possessing a mutated N-ras gene. Oncology, 51, 320 322.
  • 8
    Hancock, J.F., Paterson, H., Marshall, C.J. (1990) A polybasic domain or palmitoylation is required in addition to the CAAX motif to localise p21ras to the plasma membrane. Cell, 63, 133 139.
  • 9
    Imaizumi, M. & Breitman, T.R. (1988) Changes in c-myc, c-fms, and N-ras proto-oncogene expression associated with retinoic acid-induced monocytic differentiation of human leukaemia HL60/MRI cells. Cancer Research, 48, 6733 6738.
  • 10
    Jani, J.P., Specht, S., Stemmler, N., Blanock, K., Singh, S.V., Gupta, V., Katoh, A. (1993) Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion and Metastasis, 13, 314 324.
  • 11
    Kawata, S., Kakimoto, L.H., Ishiguro, H., Yamasaki, E., Inui, Y., Matsuzawa, Y. (1992) Effect of pravastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, on survival of AH130 hepatoma-bearing rats. Japanese Journal of Cancer Research, 83, 1120 1123.
  • 12
    Kita, T., Brown, M.S., Goldstein, J.L. (1980) Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. Journal of Clinical Investigation, 66, 1094 1100.
  • 13
    Kohl, N.E., Mosser, S.D., DeSolms, J., Giuliani, E.A., Pompliano, D.L., Graham, S.L., Smith, R.L., Scolnick, E.M., Oliff, A., Gibbs, J.B. (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor . Science, 260, 1934 1937.
  • 14
    Larsson, O. (1996) HMG-CoA reductase inhibitors: role in normal and malignant cells. Critical Reviews in Oncology/Haematology, 22, 197 212.
  • 15
    Lehninger, A.L. (1975) Biochemistry, 2nd edn. Worth, New York.
  • 16
    Mitchell, P.L.R., Clutterbuck, R.D., Powles, R.L., De Lord, C., Morilla, R., Hiorns, L.R., Titley, J., Catovsky, D., Millar, J.L. (1996) Interleukin-4 enhances the survival of severe combined immunodeficient mice engrafted with human B-cell precursor leukemia. Blood, 87, 4797 4803.
  • 17
    Newman, A., Clutterbuck, R.D., DeLord, C., Powles, R.L., Catovsky, D., Millar, J.L. (1995) The sensitivity of leukaemia bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation. Journal of Investigative Medicine, 43, 269 274.
  • 18
    Newman, A., Clutterbuck, R.D., Powles, R.L., Catovsky, D., Millar, J.L. (1997) A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leukemia and Lymphoma, 24, 533 537.
  • 19
    Newman, A., Clutterbuck, R.D., Powles, R.L., Millar, J.L. (1994) Selective inhibition of primary acute myeloid leukemia cell growth by simvastatin. Leukemia, 8, 2023 2029.
  • 20
    Pentikainen, P.J., Saraheimo, M., Schwartz, J.I., Amin, R.D., Schwartz, M.S., Brunner-Ferber, F., Rogers, J.D. (1992) Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. Journal of Clinical Pharmacology, 32, 136 140.
  • 21
    Pizer, E.S., Wood, F.D., Pasternack, G.R., Kuhajda, F.P. (1996) Fatty acid synthesis (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Research, 56, 745 751.
  • 22
    Powles, R., Lister, T.A., Oliver, R.T.D., Russell, J., Smith, C., Kay, H.E.M., McElwain, T.J., Hamilton-Fairley, G. (1974) Safe method for collecting leukaemia cells from patients with acute myeloid leukaemia for use as immunotherapy. British Medical Journal, iv, 375 379.
  • 23
    Reiss, Y., Goldstein, J.L., Seabra, M.C., Casey, P.J., Brown, M.S. (1990) Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell, 62, 81 88.
  • 24
    Rowe-Jones, D.C. (1969) Cytotoxic penetration and concentration in human malignant tumours. British Journal of Surgery, 56, 774 778.
  • 25
    Sebti, S.M., Tkalcevic, G.T., Jani, J.P. (1991) Lovastatin, a cholesterol biosynthetic inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Communications, 3, 141 147.
  • 26
    Siperstein, M.D. (1984) Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. Journal of Lipid Research, 25, 1462 1468.
  • 27
    Suzuki, M., Hori, K., Abe, I., Saito, S., Sato, H. (1981) A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin. Journal of the National Cancer Institute, 67, 663 669.
  • 28
    Thibault, A., Samid, D., Tompkins, A.C., Figg, W.D., Cooper, M.R., Hohl, R.J., Trepel, J., Liang, B., Patronas, N., Venzon, D.J., Reed, E., Myers, C.E. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clinical Cancer Research, 2, 483 491.
  • 29
    Toksoz, D., Farr, C.J., Marshall, C.J. (1989) Ras genes and acute myeloid leukaemia. British Journal of Haematology, 71, 1 6.
  • 30
    Trzaskos, J.M., Fischer, R.T., Favata, MF. (1986) Mechanistic studies of lanosterol C-32 demethylation. Journal of Biological Chemistry, 261, 16937 16942.
  • 31
    Vitols, S., Angeli, B., Juliusson, G. (1997) Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans: in vitro and in vivo studies. Lipids, 32, 255 262.
  • 32
    Wilkinson, J., 4th, Cerda, S., Cerda, S.R., Branch, S.K., Broitman, S.A. (1995) Limonene (LE) and mevinolin (MV) affect growth of the human colonic adenoCA LS174T implanted in the livers of nude mice. (Abstract). Proceedings of the Annual Meeting of the American Association of Cancer Research, 36, A1776.
  • 33
    Zar, J.H. (1984) Biostatistical Analysis, 2nd edn. Prentice-Hall, New Jersey.